Loading
A phase 3 trial of Zanzalintinib, Atezolizumab, Regorafenib in colorectal cancer, run by Exelixis, active and no longer recruiting.
Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer is a phase 3 interventional study registered as NCT05425940 by Exelixis, with 901 participants enrolled, started 2022-09-07 and due to reach its primary completion in 2026-06-16. Interventions recorded: XL092, Atezolizumab, Regorafenib. Conditions listed: Colorectal Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Atezolizumab, Anti-angiogenic therapy, Small-molecule kinase inhibitors, Colorectal cancer.
Shares Exelixis, Atezolizumab, Anti-angiogenic therapy, Small-molecule kinase inhibitors.
Shares Zanzalintinib, Exelixis, Immune checkpoint inhibitors.
Shares Zanzalintinib, Exelixis, Atezolizumab, Immune checkpoint inhibitors.
Shares Zanzalintinib, Exelixis.
Shares Exelixis, Atezolizumab, Anti-angiogenic therapy, Small-molecule kinase inhibitors.
Shares Exelixis, Anti-angiogenic therapy, Small-molecule kinase inhibitors.
Shares Regorafenib, Anti-angiogenic therapy, Small-molecule kinase inhibitors, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/